abstract |
The present invention relates to the field of oligonucleotide therapeutics, specifically where two or more antisense oligonucleotides are covalently linked by a physiologically labile linker, and a biocleavage such as a conjugate group. Polyoligonucleotide conjugates linked to a functional group. |